glp 1 press conference Experts Say GLP-1 Drugs Have Potential Use Beyond Weight Loss The Next Era in Obesity

15 , 16 This study synthesizes 21 RCTsincluding the latest CV and renal outcome studiesinvolving nearly 100,000 patients, applies incidence rate ratios (IRRs) to account for variable follow-up, incorporates trial sequential analysis, and provides the most comprehensive pooled evaluation to date of both efficacy and safety in DM and non-DM populations

Which Drug Is Generally Most Potent for Weight Loss

Lixisenatide (Adylyxin) is an exendin-4 analogue with six Lys residues added at the C terminus to confer resistance to DPP-4 (22,282)

Most neurocognitive peptides have favorable short-term safety profiles in available research, though long-term human data remains limited